BioSpace News Archive

The artificial joints and limbs market is expected to observe profitable growth across the forecast period of 2018-2026.

Biotage has managed to deal with the global challenges in the supply chain and ended 2021 with another sales record in the fourth quarter.

Humanigen, Inc. announced that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Talaris Therapeutics, Inc. announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

Sio Gene Therapies Inc., a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, provided corporate updates and financial results for its fiscal third quarter ended December 31, 2021.

IsoPlexis Corporation, the Superhuman Cell Company, announced the company will be participating in the following investor conferences.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced that company management will participate in Citi’s 2022 Immuno-Oncology Summit.

Oxurion NV will be presenting data from Part A of its two-part Phase 2 Clinical Trial assessing THR-149 for treatment of diabetic macular edema at the upcoming Angiogenesis, Exudations, and Degeneration 2022 Meeting being held virtually on February 11-12th.

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, reports positive biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA as well as favorable safety data from the ongoing adaptative clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis.

During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs.